

# Kan Gong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1050872/publications.pdf>

Version: 2024-02-01

86  
papers

1,817  
citations

279798

23  
h-index

315739

38  
g-index

97  
all docs

97  
docs citations

97  
times ranked

2742  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway. <i>Cell Death and Disease</i> , 2021, 12, 1.	6.3	223
2	Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma – a retrospective study using TCGA database. <i>Aging</i> , 2019, 11, 1633-1647.	3.1	157
3	Osteopontin as a multifaceted driver of bone metastasis and drug resistance. <i>Pharmacological Research</i> , 2019, 144, 235-244.	7.1	124
4	Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. <i>BJU International</i> , 2013, 112, 917-924.	2.5	63
5	TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss. <i>Cancer Discovery</i> , 2020, 10, 460-475.	9.4	63
6	MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma. <i>Cellular Signalling</i> , 2013, 25, 1212-1221.	3.6	59
7	Extramammary Paget's disease of scrotum – report of 25 cases and literature review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 28-33.	1.6	58
8	<sup>68</sup> Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1852-1861.	6.4	54
9	Family history of von Hippel-Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients. <i>Journal of Human Genetics</i> , 2012, 57, 238-243.	2.3	53
10	TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway. <i>International Journal of Biological Sciences</i> , 2019, 15, 587-597.	6.4	49
11	Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 276.	8.6	46
12	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. <i>Molecular Cell</i> , 2020, 77, 1294-1306.e5.	9.7	41
13	Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 269-274.	2.5	37
14	Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-1 $\alpha$ binding site in VHL protein. <i>Genetics in Medicine</i> , 2018, 20, 1266-1273.	2.4	37
15	Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 433-437.	2.5	34
16	Multilocular Cystic Renal Cell Neoplasm of Low Malignant Potential: A Series of 76 Cases. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e553-e557.	1.9	34
17	The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. <i>World Journal of Urology</i> , 2016, 34, 871-877.	2.2	33
18	Telomere Shortening Is Associated with Genetic Anticipation in Chinese Von Hippel-Lindau Disease Families. <i>Cancer Research</i> , 2014, 74, 3802-3809.	0.9	32

#	ARTICLE	IF	CITATIONS
19	Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma. <i>Aging</i> , 2020, 12, 4424-4444.	3.1	31
20	CSTP1, a Novel Protein Phosphatase, Blocks Cell Cycle, Promotes Cell Apoptosis, and Suppresses Tumor Growth of Bladder Cancer by Directly Dephosphorylating Akt at Ser473 Site. <i>PLoS ONE</i> , 2013, 8, e65679.	2.5	27
21	Risk factors for survival in patients with von Hippel-Lindau disease. <i>Journal of Medical Genetics</i> , 2018, 55, 322-328.	3.2	26
22	Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. <i>Epigenomics</i> , 2015, 7, 733-744.	2.1	25
23	Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients. <i>Oncotarget</i> , 2017, 8, 38456-38465.	1.8	25
24	The Erythropoietin/Erythropoietin Receptor Signaling Pathway Promotes Growth and Invasion Abilities in Human Renal Carcinoma Cells. <i>PLoS ONE</i> , 2012, 7, e45122.	2.5	24
25	Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models. <i>Oncotarget</i> , 2017, 8, 49839-49850.	1.8	24
26	Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population. These authors contribute equally.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 66.e1-66.e11.	1.6	21
27	Coexpression of erythropoietin and erythropoietin receptor in sporadic clear cell renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2006, 5, 582-585.	3.4	18
28	Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 6627-6639.	1.9	18
29	Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel-Lindau Disease. <i>Frontiers in Genetics</i> , 2019, 10, 867.	2.3	18
30	Mosaicism in von Hippel-Lindau disease with severe renal manifestations. <i>Clinical Genetics</i> , 2013, 84, 581-584.	2.0	17
31	Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2016, 11, 4095-4098.	1.8	17
32	Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients. <i>Cancer Medicine</i> , 2017, 6, 2131-2141.	2.8	17
33	Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. <i>Oncotarget</i> , 2017, 8, 3355-3363.	1.8	15
34	Serum carcinoembryonic antigen elevation in benign lung diseases. <i>Scientific Reports</i> , 2021, 11, 19044.	3.3	15
35	Clinicopathologic Features and Prognosis of Sporadic Bilateral Renal Cell Carcinoma: A Series of 148 Cases. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 618-624.	1.9	14
36	The BPSC: A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population. <i>Journal of Evidence-Based Medicine</i> , 2018, 11, 64-67.	2.4	14

#	ARTICLE	IF	CITATIONS
37	The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1 $\alpha$ and -2 $\alpha$ in sporadic clear cell renal carcinoma. <i>International Journal of Molecular Medicine</i> , 2010, 26, 907-12.	4.0	13
38	CLDN10 associated with immune infiltration is a novel prognostic biomarker for clear cell renal cell carcinoma. <i>Epigenomics</i> , 2021, 13, 31-45.	2.1	13
39	Comparison of laparoscopic and open cystectomy for bladder cancer: a single center of 110 cases report. <i>Translational Andrology and Urology</i> , 2012, 1, 4-8.	1.4	13
40	Fluorescence <i>in situ</i> hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma. <i>Oncotarget</i> , 2017, 8, 26106-26111.	1.8	11
41	Renal Arterial Pseudoaneurysm and Renal Arteriovenous Fistula Following Partial Nephrectomy. <i>Urologia Internationalis</i> , 2018, 100, 368-374.	1.3	11
42	Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 27 cases. <i>World Journal of Surgical Oncology</i> , 2018, 16, 16.	1.9	11
43	Clinicopathologic characteristics, therapy and outcomes of patients with primary ureteral small cell carcinoma: a case series and systematic review of the literature. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4105-4111.	2.0	10
44	The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1122.	2.8	10
45	Hemangioblastoma Instead of Renal Cell Carcinoma Plays a Major Role in the Unfavorable Overall Survival of Von Hippel-Lindau Disease Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1037.	2.8	10
46	Belzutifan: a novel therapy for von Hippel-Lindau disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 205-206.	9.6	10
47	Higher Prevalence of Novel Mutations in VHL Gene in Chinese Von Hippel-Lindau Disease Patients. <i>Urology</i> , 2014, 83, 675.e1-675.e6.	1.0	9
48	Natural history of renal tumours in von Hippel-Lindau disease: a large retrospective study of Chinese patients. <i>Journal of Medical Genetics</i> , 2019, 56, 380-387.	3.2	8
49	Comparison between completely and traditionally retroperitoneoscopic nephroureterectomy for upper tract urothelial cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 171.	1.9	7
50	Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 727-733.	1.2	7
51	Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 97-104.e1.	1.9	7
52	Suppression of renal cell carcinoma growth <i>in vivo</i> by forced expression of vascular endothelial growth inhibitor. <i>International Journal of Oncology</i> , 2013, 42, 1664-1673.	3.3	6
53	Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 543-549.	1.0	6
54	Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience. <i>World Journal of Surgical Oncology</i> , 2017, 15, 4.	1.9	6

#	ARTICLE	IF	CITATIONS
55	The Genotype-Phenotype Association of Von Hippel Lindau Disease Based on Mutation Locations: A Retrospective Study of 577 Cases in a Chinese Population. <i>Frontiers in Genetics</i> , 2020, 11, 532588.	2.3	6
56	Stereotactic radiosurgery for central nervous system hemangioblastoma in von Hippel-Lindau disease: A systematic review and meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 105912.	1.4	6
57	Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction. <i>International Journal of Biological Sciences</i> , 2022, 18, 2329-2344.	6.4	6
58	Cauda equinahemangioblastoma at L5 vertebral level related to von Hippelâ€“Lindau disease. <i>British Journal of Neurosurgery</i> , 2012, 26, 576-577.	0.8	5
59	Novel germline mutations in FLCN gene identified in two Chinese patients with Birtâ€“Hoggâ€“DubÃ© syndrome. <i>Chinese Journal of Cancer</i> , 2017, 36, 4.	4.9	5
60	Overexpression of EGFR and TGFÎ± in von Hippelâ€“Lindau-Related Central Nervous System Hemangioblastomas. <i>Frontiers in Oncology</i> , 2020, 10, 703.	2.8	5
61	Natural history of Von Hippelâ€“Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2631-2641.	2.5	5
62	Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients. <i>Journal of Medical Genetics</i> , 2022, 59, 951-956.	3.2	5
63	Prognostic Factors in Chinese Patients With Penile Invasive Squamous Cell Carcinoma. <i>Journal of Andrology</i> , 2012, 33, 1276-1281.	2.0	4
64	Intra-Familial Phenotypic Heterogeneity and Telomere Abnormality in von Hippel- Lindau Disease: Implications for Personalized Surveillance Plan and Pathogenesis of VHL-Associated Tumors. <i>Frontiers in Genetics</i> , 2019, 10, 358.	2.3	4
65	Association between vasectomy and risk of prostate cancer: a meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 962-975.	3.9	4
66	Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2017, 37, 4379-4388.	1.1	4
67	Elevated tumor markers for monitoring tumor response to immunotherapy. <i>EClinicalMedicine</i> , 2022, 46, 101381.	7.1	4
68	VHL Ser65 mutations enhance HIF2Î± signaling and promote epithelial-mesenchymal transition of renal cancer cells. <i>Cell and Bioscience</i> , 2022, 12, 52.	4.8	4
69	Distinctive clinicopathological features of Vonï½2Hippelâ€“Lindauâ€“associated hereditary renal cell carcinoma: A singleâ€“institution study. <i>Oncology Letters</i> , 2019, 17, 4600-4606.	1.8	3
70	Intronic mutation of the VHL gene associated with central nervous system hemangioblastomas in two Chinese families with Von Hippelâ€“Lindau disease: case report. <i>BMC Medical Genetics</i> , 2020, 21, 191.	2.1	3
71	Use of suppression subtractive hybridization strategy for cloning and identifying specifically expressed genes of renal cell carcinoma. <i>Science Bulletin</i> , 2001, 46, 226-229.	1.7	2
72	THE NATURAL HISTORY OF INCIDENTALLY DISCOVERED RENAL CELL CARCINOMAS (RCCS). <i>Journal of Urology</i> , 2008, 179, 332-333.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Vascular endothelial growth inhibitor 174 and its functional domains inhibit epithelial-mesenchymal transition in renal cell carcinoma cells in vitro. <i>International Journal of Molecular Medicine</i> , 2017, 40, 569-575.	4.0	1
74	Biological and clinical impact of central nervous system hemangioblastomas in Chinese patients with von Hippel-Lindau disease: implications for treatment. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 21.	1.5	1
75	Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. <i>Journal of Medical Genetics</i> , 2020, 57, 744-751.	3.2	1
76	HER2-amplified metastatic lung adenocarcinoma responds to fourth-line pyrotinib therapy: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 213.	1.0	1
77	Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelial-Mesenchymal Transition in Renal Cell Carcinoma In Vivo. <i>Anticancer Research</i> , 2017, 37, 4269-4275.	1.1	1
78	THE RELATIONSHIP OF EPO OVER-EXPRESSION TO VHL MUTATIONS AND HIF1 $\alpha$ AND 2 $\alpha$ IN SCCRCC. <i>Journal of Urology</i> , 2008, 179, 91-91.	0.4	0
79	739 CLINICAL CHARACTERISTICS OF VON HIPPEL-LINDAU DISEASE IN CHINESE PATIENTS. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
80	MP60-05 ERYTHROPOIETIN RECEPTOR MAY BECOME A TARGET FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
81	PD04-07 HIGHER PD-L1 MRNA LEVEL IN CLEAR CELL RENAL CELL CARCINOMAS IS ASSOCIATED WITH A FAVORABLE OUTCOME. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
82	PD52-10 SHORTER TELOMERE LENGTH INCREASES AGE-RELATED TUMOR RISKS IN CHINESE VON HIPPLE-LINDAU DISEASE. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
83	MP67-01 TELOMERE LENGTH AND GENETIC ANTICIPATION IN A LARGE COHORT OF CHINESE VON HIPPLE-LINDAU DISEASE. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
84	MP67-19 THE NUCLEAR GRADE AND PROGNOSIS ARE UNRELATED TO THE TNM STAGE IN MULTIFOCULAR CYSTIC RENAL CELL NEOPLASM OF LOW MALIGNANT POTENTIAL. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
85	VEGI174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma. <i>International Journal of Oncology</i> , 2018, 54, 390-398.	3.3	0
86	Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment. <i>Juntendo Medical Journal</i> , 2017, 63, 326-330.	0.1	0